Enzyme-Prodrug Strategies for Cancer Therapy [electronic resource] /

Enzyme-Prodrug Strategies for Cancer Therapy [electronic resource] /

Show other versions (1)

Antibody-directed enzyme prodrug therapy (ADEPT) directly addresses the major problem in cancer chemotherapy-its lack of selectivity. Antibody delivery combined with the amplification provided by the enzymatic activation of prodrugs enables selection to be made between tumour and normal tissue. ADEPT offers a novel field of opportunities in the therapy of systemic cancer and may be a major advance for the treatment of solid tumours. This book is the first to describe ADEPT in detail. Each chapter reviews an aspect of the immunology, enzymology, biochemistry, chemistry, and cancer chemotherapy which have been integrated into the ADEPT concept. An additional chapter describes the related approach of gene-directed enzyme prodrug therapy (GDEPT). This latter approach is still in its infancy but ADEPT has entered the clinic. The initial clinical studies with ADEPT are included and discussed in detail.

Saved in:
Bibliographic Details
Main Authors: Melton, Roger G. editor., Knox, Richard J. editor., SpringerLink (Online service)
Format: Texto biblioteca
Language:eng
Published: Boston, MA : Springer US : Imprint: Springer, 1999
Subjects:Medicine., Immunology., Internal medicine., Oncology., Biochemistry., Biomedical engineering., Medicine & Public Health., Internal Medicine., Biochemistry, general., Biomedical Engineering.,
Online Access:http://dx.doi.org/10.1007/978-1-4615-4823-2
Tags: Add Tag
No Tags, Be the first to tag this record!
id KOHA-OAI-TEST:185608
record_format koha
institution COLPOS
collection Koha
country México
countrycode MX
component Bibliográfico
access En linea
En linea
databasecode cat-colpos
tag biblioteca
region America del Norte
libraryname Departamento de documentación y biblioteca de COLPOS
language eng
topic Medicine.
Immunology.
Internal medicine.
Oncology.
Biochemistry.
Biomedical engineering.
Medicine & Public Health.
Internal Medicine.
Oncology.
Immunology.
Biochemistry, general.
Biomedical Engineering.
Medicine.
Immunology.
Internal medicine.
Oncology.
Biochemistry.
Biomedical engineering.
Medicine & Public Health.
Internal Medicine.
Oncology.
Immunology.
Biochemistry, general.
Biomedical Engineering.
spellingShingle Medicine.
Immunology.
Internal medicine.
Oncology.
Biochemistry.
Biomedical engineering.
Medicine & Public Health.
Internal Medicine.
Oncology.
Immunology.
Biochemistry, general.
Biomedical Engineering.
Medicine.
Immunology.
Internal medicine.
Oncology.
Biochemistry.
Biomedical engineering.
Medicine & Public Health.
Internal Medicine.
Oncology.
Immunology.
Biochemistry, general.
Biomedical Engineering.
Melton, Roger G. editor.
Knox, Richard J. editor.
SpringerLink (Online service)
Enzyme-Prodrug Strategies for Cancer Therapy [electronic resource] /
description Antibody-directed enzyme prodrug therapy (ADEPT) directly addresses the major problem in cancer chemotherapy-its lack of selectivity. Antibody delivery combined with the amplification provided by the enzymatic activation of prodrugs enables selection to be made between tumour and normal tissue. ADEPT offers a novel field of opportunities in the therapy of systemic cancer and may be a major advance for the treatment of solid tumours. This book is the first to describe ADEPT in detail. Each chapter reviews an aspect of the immunology, enzymology, biochemistry, chemistry, and cancer chemotherapy which have been integrated into the ADEPT concept. An additional chapter describes the related approach of gene-directed enzyme prodrug therapy (GDEPT). This latter approach is still in its infancy but ADEPT has entered the clinic. The initial clinical studies with ADEPT are included and discussed in detail.
format Texto
topic_facet Medicine.
Immunology.
Internal medicine.
Oncology.
Biochemistry.
Biomedical engineering.
Medicine & Public Health.
Internal Medicine.
Oncology.
Immunology.
Biochemistry, general.
Biomedical Engineering.
author Melton, Roger G. editor.
Knox, Richard J. editor.
SpringerLink (Online service)
author_facet Melton, Roger G. editor.
Knox, Richard J. editor.
SpringerLink (Online service)
author_sort Melton, Roger G. editor.
title Enzyme-Prodrug Strategies for Cancer Therapy [electronic resource] /
title_short Enzyme-Prodrug Strategies for Cancer Therapy [electronic resource] /
title_full Enzyme-Prodrug Strategies for Cancer Therapy [electronic resource] /
title_fullStr Enzyme-Prodrug Strategies for Cancer Therapy [electronic resource] /
title_full_unstemmed Enzyme-Prodrug Strategies for Cancer Therapy [electronic resource] /
title_sort enzyme-prodrug strategies for cancer therapy [electronic resource] /
publisher Boston, MA : Springer US : Imprint: Springer,
publishDate 1999
url http://dx.doi.org/10.1007/978-1-4615-4823-2
work_keys_str_mv AT meltonrogergeditor enzymeprodrugstrategiesforcancertherapyelectronicresource
AT knoxrichardjeditor enzymeprodrugstrategiesforcancertherapyelectronicresource
AT springerlinkonlineservice enzymeprodrugstrategiesforcancertherapyelectronicresource
_version_ 1756265395922141184
spelling KOHA-OAI-TEST:1856082018-07-30T23:07:41ZEnzyme-Prodrug Strategies for Cancer Therapy [electronic resource] / Melton, Roger G. editor. Knox, Richard J. editor. SpringerLink (Online service) textBoston, MA : Springer US : Imprint: Springer,1999.engAntibody-directed enzyme prodrug therapy (ADEPT) directly addresses the major problem in cancer chemotherapy-its lack of selectivity. Antibody delivery combined with the amplification provided by the enzymatic activation of prodrugs enables selection to be made between tumour and normal tissue. ADEPT offers a novel field of opportunities in the therapy of systemic cancer and may be a major advance for the treatment of solid tumours. This book is the first to describe ADEPT in detail. Each chapter reviews an aspect of the immunology, enzymology, biochemistry, chemistry, and cancer chemotherapy which have been integrated into the ADEPT concept. An additional chapter describes the related approach of gene-directed enzyme prodrug therapy (GDEPT). This latter approach is still in its infancy but ADEPT has entered the clinic. The initial clinical studies with ADEPT are included and discussed in detail.1 Introduction -- 1. Introduction -- References -- 2 Prodrugs in Cancer Chemotherapy -- 1. Introduction -- 2. Uses of Prodrugs in Cancer Chemotherapy -- 3. Clinical Use of Prodrugs -- References -- 3 Factors Influencing Tumor-Selective Localization of Antibody Conjugates -- 1. Introduction -- 2. Tumor Physiology -- 3. Properties of the Monoclonal Antibody Vector -- 4. Tumor Antigens -- 5. Manipulation of Tumor Antigenic Expression -- 6. Evaluation of Antigenic Targets for ADEPT -- 7.In VitroCell Culture Problems -- 8. Unforeseen Problems of Specificity -- References -- 4 Enzymes and Prodrugs Used for ADEPT -- 1. Introduction -- 2. Enzymes and Prodrugs Used for ADEPT -- 3. Conclusions -- References -- 5 The Design and Synthesis of Prodrugs for Antibody-Directed Enzyme Prodrug Therapy (ADEPT) -- 1. Introduction -- 2. Prodrugs Used in ADEPT -- 3. Summary -- References -- 6 Preparation and Purification of Antibody-Enzyme Conjugates for Therapeutic Applications -- 1. Introduction -- 2. Production of Antibody Fragments -- 3. Chemical Coupling of Antibodies to Enzymes -- 4. Alternatives to Chemical Coupling -- 5. Purification of Conjugates -- 6. Postpurification Modifications -- 7. Future Developments -- References -- 7 Phage Technology for Producing Antibody-Enzyme Fusion Proteins -- 1. Introduction -- 2. Antibody-Targeted Cancer Therapy -- 3. Potential of Engineered Antibodies for Therapy -- 4. Single-chain Fv Antibodies -- 5. The Phage System -- 6. Target Antigens -- 7. Engineered Antibody-Enzyme Fusion Proteins in ADEPT -- 8. Practical Considerations -- 9. Conclusions -- References -- 8 Early Clinical Studies with ADEPT -- 1. Introduction -- 2. Initial Clinical Studies -- 3. Second Clinical Study -- 4. Conclusions -- References -- 9 Gene-Directed Enzyme Prodrug Therapy (GDEPT) of Cancer -- 1. Introduction -- 2. Why GDEPT? -- 3. Enzymes and Prodrugs Used for GDEPT -- 4. Conclusions -- References -- Enzymes and Prodrugs Proposed for Cancer Therapy -- References.Antibody-directed enzyme prodrug therapy (ADEPT) directly addresses the major problem in cancer chemotherapy-its lack of selectivity. Antibody delivery combined with the amplification provided by the enzymatic activation of prodrugs enables selection to be made between tumour and normal tissue. ADEPT offers a novel field of opportunities in the therapy of systemic cancer and may be a major advance for the treatment of solid tumours. This book is the first to describe ADEPT in detail. Each chapter reviews an aspect of the immunology, enzymology, biochemistry, chemistry, and cancer chemotherapy which have been integrated into the ADEPT concept. An additional chapter describes the related approach of gene-directed enzyme prodrug therapy (GDEPT). This latter approach is still in its infancy but ADEPT has entered the clinic. The initial clinical studies with ADEPT are included and discussed in detail.Medicine.Immunology.Internal medicine.Oncology.Biochemistry.Biomedical engineering.Medicine & Public Health.Internal Medicine.Oncology.Immunology.Biochemistry, general.Biomedical Engineering.Springer eBookshttp://dx.doi.org/10.1007/978-1-4615-4823-2URN:ISBN:9781461548232

Similar Items